June 2025's Promising Penny Stocks For Savvy Investors
In This Article:
As the U.S. markets navigate a landscape marked by geopolitical tensions and fluctuating oil prices, investors are keenly observing shifts in major indices like the Dow Jones and S&P 500. For those interested in exploring beyond established giants, penny stocks—often representing smaller or emerging companies—remain an intriguing investment area despite their somewhat outdated moniker. By focusing on financially robust penny stocks, investors can uncover potential opportunities that balance risk with promising growth prospects.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Financial Health Rating |
| Imperial Petroleum (IMPP) | $3.37 | $115.98M | ★★★★★★ |
| New Horizon Aircraft (HOVR) | $1.87 | $58.69M | ★★★★★★ |
| Waterdrop (WDH) | $1.34 | $484.63M | ★★★★★★ |
| Greenland Technologies Holding (GTEC) | $2.00 | $34.79M | ★★★★★★ |
| WM Technology (MAPS) | $1.02 | $171.54M | ★★★★★★ |
| Perfect (PERF) | $1.82 | $185.36M | ★★★★★★ |
| Flexible Solutions International (FSI) | $4.25 | $53.75M | ★★★★★★ |
| BAB (BABB) | $0.84 | $6.1M | ★★★★★★ |
| Lifetime Brands (LCUT) | $3.71 | $83.16M | ★★★★★☆ |
| TETRA Technologies (TTI) | $3.48 | $463.09M | ★★★★☆☆ |
Click here to see the full list of 724 stocks from our US Penny Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Genelux
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Genelux Corporation is a clinical-stage biopharmaceutical company specializing in the development of oncolytic viral immunotherapies for challenging solid tumors, with a market cap of $114.14 million.
Operations: Genelux Corporation has not reported any revenue segments.
Market Cap: $114.14M
Genelux Corporation, a clinical-stage biopharmaceutical company with a market cap of US$114.14 million, remains pre-revenue with no substantial revenue streams reported. Despite having sufficient cash runway for over a year and being debt-free, the company faces significant challenges including recent auditor doubts about its ability to continue as a going concern. The stock has experienced high volatility and significant insider selling recently. Genelux's most advanced product candidate, Olvi-Vec, is undergoing multiple trials but the company remains unprofitable with losses increasing by 25.6% annually over the past five years.
Quince Therapeutics
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Quince Therapeutics, Inc. is a biopharmaceutical company dedicated to acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases, with a market cap of $65.02 million.